320 related articles for article (PubMed ID: 28494723)
1. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
2. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
[TBL] [Abstract][Full Text] [Related]
4. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
5. Vaccines in leishmaniasis: advances in the last five years.
Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous leishmaniasis: progress towards a vaccine.
Launois P; Tacchini-Cottier F; Kieny MP
Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis.
Kedzierski L
Hum Vaccin; 2011 Nov; 7(11):1204-14. PubMed ID: 22048116
[TBL] [Abstract][Full Text] [Related]
8. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
[TBL] [Abstract][Full Text] [Related]
9. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
Kumar A; Samant M
Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
[TBL] [Abstract][Full Text] [Related]
11. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
12. Visceral leishmaniasis: immunology and prospects for a vaccine.
Kaye PM; Aebischer T
Clin Microbiol Infect; 2011 Oct; 17(10):1462-70. PubMed ID: 21851483
[TBL] [Abstract][Full Text] [Related]
13. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
14. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
Lakshmi BS; Wang R; Madhubala R
Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
[TBL] [Abstract][Full Text] [Related]
15. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
Pandey SC; Kumar A; Samant M
Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
[TBL] [Abstract][Full Text] [Related]
16. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
17. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
18. Innate immunity and Leishmania vaccination strategies.
Birnbaum R; Craft N
Dermatol Clin; 2011 Jan; 29(1):89-102. PubMed ID: 21095533
[TBL] [Abstract][Full Text] [Related]
19. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
Anand S; Madhubala R
Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
[TBL] [Abstract][Full Text] [Related]
20. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
